Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Galderma Holding SA currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio is distributed across 3 distinct art units, suggesting that the company's innovations span several specialized sub-sectors of the pharmaceutical field. This distribution is matched by the involvement of distinct examiners, meaning each pending action is being reviewed by a different official.
WENHAN LI is the busiest examiner for the portfolio, currently responsible for 1 pending office action. Because the pending office actions are spread across distinct examiners and art units, the company faces a diverse set of examination perspectives. This lack of concentration indicates that the prosecution of these cases is likely independent of one another, despite falling under the same broad technology area. The 1 busiest examiner pending count suggests that no single official is overwhelmed by the company's current filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, WENHAN | 1 | — | — |
| STIGELL, THEODORE J | 1 | 78.3% | +14.9% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17347148 | HYDROGEL COMPOSITIONS ENCAPSULATING SOLID PARTICLES | KWON, JOHN SEUNGJAI | 244d overdue |
| 17976243 | SYRINGE FOR IMPROVED INJECTION AND ASPIRATION | STIGELL, THEODORE J | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 3783 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18899935 | PERSONAL CARE COMPOSITIONS FOR SENSITIVE SKIN AND METHODS OF USE | LI, WENHAN | 1614 | §103 | Final Rejection | — | Pending | Sep 27, 2024 |
| 17976243 | SYRINGE FOR IMPROVED INJECTION AND ASPIRATION | STIGELL, THEODORE J | 3783 | §103 | Final Rejection | — | Pending | Oct 28, 2022 |
| 17347148 | HYDROGEL COMPOSITIONS ENCAPSULATING SOLID PARTICLES | KWON, JOHN SEUNGJAI | 1615 | §103 | Final Rejection | 244d overdue | Pending | Jun 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial